Search

Your search keyword '"Jensen, Dorte Vendelbo"' showing total 23 results
Start Over Author "Jensen, Dorte Vendelbo" Database OpenAIRE
23 results on '"Jensen, Dorte Vendelbo"'

1. Biosimilar-to-Biosimilar Switching in Routine Care - Results on > 1,600 Patients with Inflammatory Arthritis in the DANBIO Registry

Author

Nabi, Hafsah, Hendricks, Oliver, Jensen, Dorte Vendelbo, Loft, Anne Gitte, Pedersen, Jens, Just, Søren, Danebod, Kamilla, Munk, Heidi, Kristensen, Salome, Manilo, Natalia, Colic, Ada, Linauskas, Asta, Thygesen, Pia Høger, Christensen, Louise, Kalisz, Maren Høgberget, Lomborg, Niels, Chrysidis, Stavros, Raun, Johnny, Andersen, Marlene, Mehnert, Frank, Krogh, Niels Steen, Hetland, Merete L, and Glintborg, Bente

Published
2022

3. Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab:Nationwide observational study emulating a randomised clinical trial

Author

Nabi, Hafsah, Georgiadis, Stylianos, Loft, Anne Gitte, Hendricks, Oliver, Jensen, Dorte Vendelbo, Andersen, Marlene, Chrysidis, Stavros, Colic, Ada, Danebod, Kamilla, Hussein, Mohamad Redha, Kalisz, Maren Høgberget, Kristensen, Salome, Lomborg, Niels, Manilo, Natalia, Munk, Heidi Lausten, Pedersen, Jens Kristian, Raun, Johnny Lillelund, Mehnert, Frank, Krogh, Niels Steen, Hetland, Merete Lund, and Glintborg, Bente

Subjects
Adult, Male, Comparative Effectiveness Research, Drug Substitution, Denmark, biosimilar pharmaceuticals, Arthritis, Psoriatic, Adalimumab, Middle Aged, Medication Adherence, Arthritis, Rheumatoid, Cohort Studies, Logistic Models, Treatment Outcome, Antirheumatic Agents, adalimumab, Humans, Spondylarthropathies, Female, epidemiology, Registries, Biosimilar Pharmaceuticals, Aged, Proportional Hazards Models
Abstract

Objectives: In 2018, a nationwide mandatory switch from originator to biosimilar adalimumab was conducted in Denmark. The available biosimilar was GP2017 (Hyrimoz) in Eastern regions and SB5 (Imraldi) in Western regions. We aimed to assess the comparative effectiveness of GP2017 versus SB5 in patients with rheumatoid arthritis (RA)/psoriatic arthritis (PsA)/axial spondyloarthritis (AxSpA). Methods: Observational cohort study based on the DANBIO registry with geographical cluster pseudo-randomisation, analysed by emulating a randomised clinical trial. Main outcome was adjusted 1-year treatment retention (Cox regression). Furthermore, 6 months' remission rates (logistic regression), reasons for withdrawal and back-switching to originator were investigated (overall and stratified by indication). Results: Overall, of 1570 eligible patients, 1318 switched and were included (467 RA/321 PsA/530 AxSpA); 623 (47%) switched to GP2017, 695 (53%) to SB5. Baseline characteristics of the two clusters were largely similar, but some differences in registration practice were observed. The combined 1-year retention rate for the two biosimilars was 89.5%. Compared with SB5, estimated risk of withdrawal for GP2017 was lower (HR 0.60; 95% CI 0.42 to 0.86) and 6 months' remission rate was higher (OR 1.72; 95% CI 1.25 to 2.37). Stratified analyses gave similar results (statistically significant for RA). During 1 year, 8.5% and 12.9% withdrew GP2017 and SB5, respectively (primarily lack of effect and adverse events), of whom 48 patients (3.6%) back-switched. Conclusion: This head-to-head comparison of GP2017 versus SB5 following a mandatory switch from the originator indicated differences in effectiveness in routine care. This may reflect a true difference, but other explanations, for example, differences in excipients, differences between clusters and residual confounding cannot be ruled out.

Published
2021

4. Biosimilar to Biosimilar Infliximab Switching in Real-world Patients with Inflammatory Arthritis Followed in the Danish DANBIO Registry: Switch from Originator Infliximab to CT-P13 and Then to GP1111

Author

Nabi, Hafsah, Glintborg, Bente, Loft, Anne Gitte, Hendricks, Oliver, Pedersen, Jens Kristian, Just, Søren Andreas, Ahmed, Rabiah, Danebod, Kamilla, Munk, Heidi, Colic, Ada, Linauskas, Asta, Jensen, Dorte Vendelbo, Raun, Johnny, Grydehøj, Jolanta, Christensen, Louise Brot, Manilo, Natalia, Lomborg, Niels, Kristensen, Salome, Mehnert, Frank, Krogh, Niels Steen, and Hetland, Merete

Published
2021

5. Anxiety and concerns related to the work situation during the COVID-19 Self-protection strategies, health behavior and disease activity during the first wave, reopening and second wave of the COVID-19 pandemic in >7000 Danish patients with inflammatory arthritis

Author

Glintborg, Bente, Jensen, Dorte Vendelbo, Engel, Sara, Terslev, Lene, Pfeiffer-Jensen, Mogens, Hendricks, Oliver, Østergaard, Mikkel, Rasmussen, Simon Horskjær, Adelsten, Thomas, Colic, Ada, Danebod, K., Kildemand, Malene, Loft, AG, Munk, Heidi Lausten, Pedersen, Jens Kristian, Sørensen, C.M., Østgård, René, Agerbo, Jette Nørgaard, Krogh, N. S., Ziegler, Connie, and Hetland, Merete Lund

Published
2021

6. Anxiety and concerns related to the work situation during the COVID-19 pandemic in >5000 patients with inflammatory rheumatic disease followed in the Danis DANBIO registry, results from a nationwide questionnaire, POS 721

Author

Glintborg, Bente, Jensen, Dorte Vendelbo, Engel, Sara, Terslev, Lene, Pfeiffer-Jensen, Mogens, Hendricks, Oliver, Østergaard, Mikkel, Horskjær Rasmussen, Simon, Adelsten, Thomas, Colic, Ada, Danebod, K., Kildemand, Malene, Loft, Anne Gitte, Munk, Heidi Lausten, Pedersen, Jens Kristian, Østgård, René, Møller Sørensen, Christian, Krogh, Niels Steen, Nørgaard Agerbo, Jette, Ziegler, Connie, and Hetland, Merete Lund

Published
2021

8. Clinical outcomes from a nationwide non-medical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow-up:Results from The DANBIO Registry

Author

Glintborg, Bente, Sørensen, Inge Juul, Loft, Anne Gitte, Espesen, Jakob, Lindegaard, Hanne, Jensen, Dorte Vendelbo, Danebod, K., Dieperink, Sabine Sparre, Hendricks, Oliver, Hansen, Inger Marie Jensen, Linauskas, Asta, Kristensen, Salome, Andersen, Lis Smedegaard, Hossein, M., Nordin, H., Andersen, B. L., Chrysidis, Stavros, Raun, J.L., Manilo, Natalia, Grydehøj, Jolanta, Dalgaard, E. B., Dalsgaard Pedersen, Dorte, Krogh, Niels Steen, and Hetland, Merete Lund

Published
2017

9. Using an electronic platform interactively to improve treatment outcome in patients with rheumatoid arthritis:new developments from the DANBIO registry

Author

Merete Lund Hetland, Krogh, Niels Steen, Horslev-Petersen, Kim, Schiottz-Christensen, Berit, Sorense, Inge Juul, and Jensen, Dorte Vendelbo

Subjects
DANBIO registry, Interactive electronic platform, Rheumatoid arthritis
Abstract

OBJECTIVES: Electronic platforms have been developed to help the clinician monitor disease activity in rheumatoid arthritis (RA) to support at treat-to-target strategy. We present an initiative to interactively improve disease control in patients with rheumatoid arthritis.METHODS: In patients who presented with one or more swollen joints AND moderate/high disease activity (i.e. either CDAI≥10.1 and/or DAS-28CRP>3.2, which is automatically calculated in the DANBIO registry), a red alert was shown, which activated a pop-up: "This patient has at least one swollen joint AND either CDAI≥ 10.1 or DAS28CRP>3.2. Which action do you as a physician take today: □ Intensify treatment, □ Treatment intensification is not possible currently/awaiting results of additional investigations, □ No further treatment intensification is possible, □ The patient does not want to intensify treatment, □ Other decisions taken" RESULTS: Of 21,056 patients with RA, 40% fulfilled the criteria for getting the alert message. The pop-up was activated and completed by the physician in 65% of those (5,428 patients). Treatment was intensified in 67%. In 2% of patients, no additional treatment intensification was possible, and 8% of the patients objected to intensification.CONCLUSIONS: In >8,000 RA patients who presented with objective signs of active disease in routine care, an interactive feature of the DANBIO registry was introduced, which prompted the physician to take action and consider treatment intensification. In two-thirds of the cases, the treating physician reported that treatment was intensified.

Published
2016

10. Using an electronic platform interactively to improve treatment outcome in patients with rheumatoid arthritis: new developments from the DANBIO registry

Author

Merete L, Hetland, Niels Steen, Krogh, Kim, Hørslev-Petersen, Berit, Schiøttz-Christensen, Inge Juul, Sørensen, and Jensen, Dorte Vendelbo

Subjects
Male, Denmark, Patient Selection, Reminder Systems, Middle Aged, Decision Support Systems, Clinical, Severity of Illness Index, Decision Support Techniques, Drug Therapy, Computer-Assisted, Arthritis, Rheumatoid, Treatment Outcome, Rheumatology, Predictive Value of Tests, Risk Factors, Antirheumatic Agents, Surveys and Questionnaires, Humans, Female, Registries, Medical Informatics, Aged
Abstract

Electronic platforms have been developed to help the clinician monitor disease activity in rheumatoid arthritis (RA) to support at treat-to-target strategy. We present an initiative to interactively improve disease control in patients with rheumatoid arthritis.In patients who presented with one or more swollen joints AND moderate/high disease activity (i.e. either CDAI≥10.1 and/or DAS-28CRP3.2, which is automatically calculated in the DANBIO registry), a red alert was shown, which activated a pop-up: "This patient has at least one swollen joint AND either CDAI≥ 10.1 or DAS28CRP3.2. Which action do you as a physician take today: □ Intensify treatment, □ Treatment intensification is not possible currently/awaiting results of additional investigations, □ No further treatment intensification is possible, □ The patient does not want to intensify treatment, □ Other decisions taken" RESULTS: Of 21,056 patients with RA, 40% fulfilled the criteria for getting the alert message. The pop-up was activated and completed by the physician in 65% of those (5,428 patients). Treatment was intensified in 67%. In 2% of patients, no additional treatment intensification was possible, and 8% of the patients objected to intensification.In8,000 RA patients who presented with objective signs of active disease in routine care, an interactive feature of the DANBIO registry was introduced, which prompted the physician to take action and consider treatment intensification. In two-thirds of the cases, the treating physician reported that treatment was intensified.

Published
2016

11. Three months’ clinical outcomes from a nationwide non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis:Results from The Danbio Registry

Author

Glintborg, Bente, Sørensen, Inge Juul, Jensen, Dorte Vendelbo, Steen Krogh, Niels, Loft, Anne Gitte, Colic, Ada, Espesen, Jacob, Olsen, Jimmi, Hendricks, Oliver, Grydehøj, Jolanta, Jensen Hansen, Inger Marie, V.Sørensen, Michael, Chrysidis, Stavros, Manilo, Natalia, Klarlund, Mette, Andersen, Lis Smedegaard, Nordin, Henrik, and Hetland, Merete Lund

Published
2016

12. Non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis:impact on s-infliximab and antidrug-antibodies. Results from the Danish Rheumatologic Biobank and the DANBIO registry

Author

Glintborg, Bente, Kringelbach, Tina, Høgdall, Estrid, Sørensen, Inge Juul, Jensen, Dorte Vendelbo, Loft, Anne Gitte, Hendricks, Oliver, Jensen Hansen, Inger Marie, Bolstad, Nils, Warren, David J., Gehin, Johanna, Goll, Guro, Grøn, Kathrine, Eng, Grith, Enevold, Christian, Nielsen, Claus Henrik, Johansen, Julia S., and Hetland, Merete L.

Published
2016

13. DANBIO:Danish Rheumatology Database

Author

Hetland, Merete Lund, Jensen, Dorte Vendelbo, and Tarp, Ulrik

Subjects
Internet, Databases, Factual, Quality Assurance, Health Care, Arthritis, Denmark, Humans, Registries, Severity of Illness Index
Published
2012

16. Impact of Tumour Necrosis Factor Inhibitor Treatment On Hand Bone Loss in Rheumatoid Arthritis Patients Treated in Clinical Practice. Results From the Nationwide Danish Danbio Registry

Author

Ornbjerg, Lykke Midtboll, Ostergaard, Mikkel, Boyesen, Pernille, Jensen, Trine David, Thormann, Anja, Tarp, Ulrik, Bohme, Wolfgang, Dencker, Ditte, Hanne Merete Lindegaard, Poulsen, Uta Engling, Hansen, Annette, Ringsdal, Vibeke Stevenius, Schlemmer, Annette, Graudal, Niels, Andersen, Anne Rodgaard, Espesen, Jakob, Kollerup, Gina, Christensen, Torben Grube, Pelck, Randi, Glintborg, Bente, Madsen, Ole Rintek, Jensen, Dorte Vendelbo, Majgaard, Ole, and Hetland, Merete L.

17. Tumour Necrosis Factor Inhibitor Treatment Normalises Hand Bone Loss in a Minority of Rheumatoid Arthritis Patients Treated in Clinical Practice. Results from the Copenhagen Osteoarthritis Study and the Danbio Registry

Author

Ornbjerg, Lykke Midtboll, Ostergaard, Mikkel, Jensen, Trine David, Mortensen, Pernille Bach, Hyldstrup, Lars, Boyesen, Pernille, Thormann, Anja, Tarp, Ulrik, Bohme, Wolfgang, Hanne Merete Lindegaard, Poulsen, Uta Engling, Hansen, Annette, Schlemmer, Annette, Graudal, Niels, Andersen, Anne Rodgaard, Espesen, Jakob, Kollerup, Gina, Glintborg, Bente, Madsen, Ole Rintek, Jensen, Dorte Vendelbo, and Hetland, Merete Lund

18. One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the DANBIO registry

Author

Bente Glintborg, Sørensen, I. J., Omerovic, E., Mehnert, F., Manilo, N., Kamilla Danebod, Jensen Dorte Vendelbo, Henrik Nordin, Anne Gitte Loft, Oliver Hendricks, Chrysidis, S., Andersen, B. L., Johnny Lillelund Raun, Hanne Merete Lindegaard, Jakob Espesen, Jakobsn, S. H., Inger Marie Jensen Hansen, Dalsgaard, E. B., Krogh, N., and Merete Lund Hetland

19. One-Year Clinical Outcomes in 1623 Patients with Inflammatory Arthritis Who Switched from Originator to Biosimilar Etanercept - an Observational Study from the Danish Danbio Registry

Author

Glintborg, Bente, Omerovic, Emina, Danebod, Kamilla, Jensen, Dorte Vendelbo, Nordin, Henrik, Loft, Anne Gitte, Chrysidis, Stavros, Raun, Johnny Lillelund, Hendricks, Oliver, Lindegaard, Hanne, Espesen, Jakob, Jakobsen, Susanne, Hansen, Inger Marie J., Grydehoj, Jolanta, Dalgaard, Emil, Pedersen, Dorte Dalsgaard, Manilo, Natalia, Andersen, Lis Smedegaard, Kristensen, Salome, Linauskas, Asta, Krogh, Niels Steen, and Merete Lund Hetland

Abstract

number 1550

20. Non-Medical Switch from Originator to Biosimilar Infliximab in Patients with Inflammatory Arthritis - Impact on s-Infliximab and Antidrug-Antibodies. Results from the Danish Rheumatologic Biobank and the Danbio Registry

Author

Glintborg, Bente, Kringelbach, Tina Marie, Hogdall, Estrid, Sorensen, Inge Juul, Jensen, Dorte Vendelbo, Loft, Anne Gitte, Hendricks, Oliver, Hansen, Inger Marie Jensen, Linauskas, Asta, Kristensen, Salome, Hanne Merete Lindegaard, Nordin, Henrik, Bolstad, Nils, Warren, David, Gehin, Johanna, Goll, Guro Lovik, Gron, Kathrine Lederballe, Eng, Grith, Enevold, Christian, Nielsen, Claus Henrik, Johansen, Julia Sidenius, and Hetland, Merete Lund

21. Risk Factors for Radiographic Progression During TNF-Inhibitor Treatment in 932 Rheumatoid Arthritis Patients Treated in Clinical Practice: Results From the Nationwide Danish Danbio Registry

Author

Ornbjerg, Lykke Midtboll, Ostergaard, Mikkel, Boyesen, Pernille, Thormann, Anja, Tarp, Ulrik, Bohme, Wolfgang, Dencker, Ditte, Lindegaard, Hanne M., Poulsen, Uta Engling, Hansen, Annette, Ringsdal, Vibeke Stevenius, Schlemmer, Annette, Graudal, Niels, Andersen, Anne Rodgaard, Espesen, Jakob, Kollerup, Gina, Christensen, Torben Grube, Pelck, Randi, Glintborg, Bente, Madsen, Ole Rintek, Jensen, Dorte Vendelbo, Majgaard, Ole, and Merete Lund Hetland

23. One-year clinical outcomes in 1621 patients with inflammatory arthritis who switched from originator to biosimilar etabercept. An observational study from the Danish DANBIO registry

Author

Oliver Hendricks, Bente Glintborg, Emina Omerovic, Kamilla Danebod, Jensen Dorte Vendelbo, Henrik Nordin, Anne Gitte Loft, Stavros Chrysidis, Johnny Lillelund Raun, Hanne Merete Lindegaard, Jakob Espesen, Susanne Jakobsen, Inger Marie Jensen Hansen, Jolanta Grydehøj, Emil Barner Dalgaard, Dorte Dalsgaard Pedersen, Natalia Manilo, Lis Smedegaard Andersen, Salome Kristensen, Asta Linauskas, Niels Steen Krogh, and Merete Lund Hetland

Catalog

Books, media, physical & digital resources
See catalog results